In this post, I link to and excerpt from the American Academy of Pediatrics 2021 Guidelines “Evaluation and Management of Well-Appearing Febrile Infants 8 to 60 Days Old” [PubMed Abstract] [Full-Text HTML] [Full-Text PDF]. Pediatrics. 2021 Aug;148(2):e2021052228.
Statement of Correction for Robert H. Pantell, Kenneth B. Roberts, William G. Adams, et al. Clinical Practice Guideline: Evaluation and Management of Well-Appearing Febrile Infants 8 to 60 Days Old. Pediatrics. 2021;148(2):e2021052228.Pediatrics. 2021 Nov;148(5):e2021054063. doi: 10.1542/peds.2021-054063. Epub 2021 Oct 29.PMID: 34716222 No abstract available.
This guideline addresses the evaluation and management of well-appearing, term infants, 8 to 60 days of age, with fever ≥38.0°C. Exclusions are noted. After a commissioned evidence-based review by the Agency for Healthcare Research and Quality, an additional extensive and ongoing review of the literature, and supplemental data from published, peer-reviewed studies provided by active investigators, 21 key action statements were derived. For each key action statement, the quality of evidence and benefit-harm relationship were assessed and graded to determine the strength of recommendations. When appropriate, parents’ values and preferences should be incorporated as part of shared decision-making. For diagnostic testing, the committee has attempted to develop numbers needed to test, and for antimicrobial administration, the committee provided numbers needed to treat. Three algorithms summarize the recommendations for infants 8 to 21 days of age, 22 to 28 days of age, and 29 to 60 days of age. The recommendations in this guideline do not indicate an exclusive course of treatment or serve as a standard of medical care. Variations, taking into account individual circumstances, may be appropriate.
Copyright © 2021 by the American Academy of Pediatrics.
- New AAP guidelines for evaluation and treatment of infants 8-60 days old.J Pediatr. 2021 Nov;238:338-342. doi: 10.1016/j.jpeds.2021.08.058.PMID: 34702503 No abstract available.
- Sufficient Blood Culture Volume.Pediatrics. 2022 Jan 1;149(1):e2021055005C. doi: 10.1542/peds.2021-055005C.PMID: 34966921 No abstract available.
- Authors’ Response.Pediatrics. 2022 Jan 1;149(1):e2021055005B. doi: 10.1542/peds.2021-055005B.PMID: 34966934 No abstract available.
- Commentary on New Guidelines for the Evaluation and Management of the Febrile Young Infant.Pediatrics. 2022 Jan 1;149(1):e2021055005A. doi: 10.1542/peds.2021-055005A.PMID: 34966935 No abstract available.
- Authors’ Response.Pediatrics. 2022 Jan 1;149(1):e2021055005D. doi: 10.1542/peds.2021-055005D.PMID: 34966943 No abstract available.
Evaluation and Management of Well-Appearing Febrile Infants 8 to 60 Days Old has been cited by:
- Clinical manifestations and disease severity of SARS-CoV-2 infection among infants in Canada.PLoS One. 2022 Aug 24;17(8):e0272648. doi: 10.1371/journal.pone.0272648. eCollection 2022.PMID: 36001553 Free PMC article.
- Improving the Evidence-based Care of Febrile Neonates: A Quality Improvement Initiative.Pediatr Qual Saf. 2022 Aug 1;7(4):e583. doi: 10.1097/pq9.0000000000000583. eCollection 2022 Jul-Aug.PMID: 35928020 Free PMC article.
- Clinical management and outcomes for febrile infants 29-60 days evaluated in community emergency departments.J Am Coll Emerg Physicians Open. 2022 Jun 17;3(3):e12754. doi: 10.1002/emp2.12754. eCollection 2022 Jun.PMID: 35765310 Free PMC article.
- Reassessing the Performance of the “Step-By-Step” Approach to Febrile Infants 90 Days of Age and Younger in the Context of the COVID-19 Pandemic: A Multicentric Retrospective Study.Pediatr Infect Dis J. 2022 Sep 1;41(9):e365-e368. doi: 10.1097/INF.0000000000003614. Epub 2022 Jun 15.PMID: 35703301 Free PMC article.
- COVID-19 Infection in Well-Appearing 30- to 90-Day-Old Infants with Fever without a Source.J Trop Pediatr. 2022 Jun 6;68(4):fmac046. doi: 10.1093/tropej/fmac046.PMID: 35666180 Free PMC article.